<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03953079</url>
  </required_header>
  <id_info>
    <org_study_id>GBV-102-002</org_study_id>
    <nct_id>NCT03953079</nct_id>
  </id_info>
  <brief_title>A Depot Formulation of Sunitinib Malate (GB-102) Compared to Aflibercept in Subjects With Wet AMD</brief_title>
  <acronym>ALTISSIMO</acronym>
  <official_title>A Phase 2b Multicenter Dose-Ranging Study Evaluating the Safety and Efficacy of Sunitinib Malate Depot Formulation (GB-102) Compared to Aflibercept in Subjects With Neovascular (Wet) Age-related Macular Degeneration (ALTISSIMO Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Graybug Vision</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Graybug Vision</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 2b, multicenter, visual examiner-masked, randomized active-controlled, parallel-arm
      design study to evaluate the safety and duration of repeated IVT injections of 3 dose levels
      of GB‑102 compared with aflibercept.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase 2b, multicenter, visual examiner-masked, randomized active-controlled, parallel-arm
      design study to evaluate the safety and duration of the effect of GB-102, as measured by time
      to first rescue treatment across multiple dose levels of GB-102 administered every 6 months
      as compared to intravitreal (IVT) aflibercept administered every 2 months in subjects with
      neovascular (wet) age-related macular degeneration who have received prior induction with
      anti-vascular endothelial growth factor (VEGF)
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 26, 2019</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel-arm design</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Visual examiner-masked</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Kaplan-Meier analyses of the proportion of treated subjects remaining rescue-free through Month 10</measure>
    <time_frame>Baseline through 10 months</time_frame>
    <description>Assessment of the percentage of subjects remaining rescue free at Month 10</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in best corrected visual acuity (BCVA) as assessed using the early treatment of diabetic retinopathy (ETDRS) protocol (range, 0 [worst] to 100 [best]) to the average BCVA ETDRS letter score at Months 9 and 10</measure>
    <time_frame>Baseline through 10 months</time_frame>
    <description>Assessment of change in BCVA from baseline compared to the average BCVA scores (ETDRS) at Months 9 and 10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in BCVA (ETDRS letter score) to all visits</measure>
    <time_frame>Baseline through 12 months</time_frame>
    <description>BCVA = best corrected visual acuity; ETDRS = early treatment of diabetic retinopathy
BCVA ETDRS range = 0 (worst) to 100 (best)
Assessment of change in BCVA (ETDRS letter score) from baseline at all visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in central subfield thickness (CST [μm]) to the average of Months 9 and 10 scores</measure>
    <time_frame>Baseline through 10 months</time_frame>
    <description>Assessment of change in CST (μm) measurement from baseline compared to the average OCT CST (μm) measurements at Months 9 and 10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in CST (μm) at all visits</measure>
    <time_frame>Baseline through 12 months</time_frame>
    <description>CST = central subfield thickness
Assessment of change in CST (μm) measurement from baseline at all visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from thickest observed CST (μm) prior to enrollment (pre-enrollment baseline) at all visits</measure>
    <time_frame>Screening through 12 months</time_frame>
    <description>CST = central subfield thickness
Assessment of change from thickest observed CST (μm) prior to enrollment (pre-enrollment baseline) compared to CST (μm) at all visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to rescue treatment</measure>
    <time_frame>Baseline through 12 months</time_frame>
    <description>Assessment of time to rescue treatment over 12 months of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean number of intravitreal injections</measure>
    <time_frame>Baseline through 12 months</time_frame>
    <description>Assessment of the mean number of intravitreal injections over 12 months of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with absence of exudation (intra-/sub-retinal fluid/cystoid edema) at Months 9 and 12 of treatment</measure>
    <time_frame>Baseline through 12 months</time_frame>
    <description>Assessment of the percentage of subjects with absence of exudation (intra-/sub-retinal fluid/cystoid edema) at Months 9 and 12 of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who gained ≥ 15 ETDRS letters at Months 9 and 12 of treatment</measure>
    <time_frame>Baseline through 12 months</time_frame>
    <description>ETDRS = early treatment of diabetic
Assessment of the proportion of subjects who gained ≥ 15 ETDRS letters at Months 9 and 12 of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who lost ≥ 15 ETDRS letters at Months 9 and 12 of treatment</measure>
    <time_frame>Baseline through 12 months</time_frame>
    <description>ETDRS = early treatment of diabetic
Assessment of the percentage of subjects who lost ≥ 15 ETDRS letters at Months 9 and 12 of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with BCVA worse than 20/200 (Snellen equivalent) at Months 9 and 12 of treatment</measure>
    <time_frame>Baseline through 12 months</time_frame>
    <description>Assessment of the percentage of subjects with BCVA worse than 20/200 (Snellen equivalent) at Months 9 and 12 of treatment
A vision score of 20/20 is considered normal. A vision score of 20/200 is considered legally blind.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Neovascular Age-Related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>GB-102 Dose 2 (1 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive intravitreal (IVT) GB-102 (1 mg) in the study eye at Baseline and Month 6 and sham at Months 2, 4, 8 and 10.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GB-102 Dose 3 (2 mg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive intravitreal (IVT) GB-102 (2 mg) in the study eye at Baseline and Month 6 and sham at Months 2, 4, 8 and 10.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aflibercept 2 mg Dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive intravitreal (IVT) aflibercept 2 mg in the study eye at Baseline, Months 2, 4, 6, 8 and 10.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drug: GB-102</intervention_name>
    <description>Intravitreal injection of GB-102</description>
    <arm_group_label>GB-102 Dose 2 (1 mg)</arm_group_label>
    <arm_group_label>GB-102 Dose 3 (2 mg)</arm_group_label>
    <other_name>Sunitinib malate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aflibercept</intervention_name>
    <description>Intravitreal injection of aflibercept (2 mg dose)</description>
    <arm_group_label>Aflibercept 2 mg Dose</arm_group_label>
    <other_name>Eylea</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females ≥ 50 years of age

          -  Presence of a CNV lesion secondary to AMD treated with at least 3 prior IVT injections
             of an anti-VEGF agent (aflibercept, bevacizumab, or ranibizumab).

          -  Demonstrated response to prior anti-VEGF treatment since diagnosis

          -  BCVA of 35 letters or better

        Exclusion Criteria:

          -  History, within 6 months prior to screening, of any of the following: myocardial
             infarction, any cardiac event requiring hospitalization, treatment for acute
             congestive heart failure, transient ischemic attack, or stroke

          -  Uncontrolled hypertension, diabetes mellitus or IOP

          -  Chronic renal disease

          -  Abnormal liver function

          -  Women who are pregnant or lactating
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chief Medical Officer</last_name>
    <role>Study Director</role>
    <affiliation>Graybug Vision, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Retinal Consultants AZ</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85296</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retinal Research Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Retina Research Consultants</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retinal Diagnostic Center of Northern California</name>
      <address>
        <city>Campbell</city>
        <state>California</state>
        <zip>95008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Retina Partners</name>
      <address>
        <city>Encino</city>
        <state>California</state>
        <zip>91436</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Consultants of Orange County</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern California Retina Vitreous Associates Medical Group, Inc.</name>
      <address>
        <city>Mountain View</city>
        <state>California</state>
        <zip>94040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Coast Retina Medical Group, Inc.</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Retina Consultants - CRC</name>
      <address>
        <city>Santa Barbara</city>
        <state>California</state>
        <zip>93103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bay Area Retina Associates</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Specialty Retina Center</name>
      <address>
        <city>Coral Springs</city>
        <state>Florida</state>
        <zip>32503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Retina Institute</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806-1101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Specialty Institute</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <zip>32503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eye Associates of Pinellas</name>
      <address>
        <city>Pinellas Park</city>
        <state>Florida</state>
        <zip>33782</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeast Retina Center</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Consultants of Hawaii</name>
      <address>
        <city>'Aiea</city>
        <state>Hawaii</state>
        <zip>96701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Retina and Macula</name>
      <address>
        <city>Lemont</city>
        <state>Illinois</state>
        <zip>60439</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wolfe Eye Clinic - West Des Moines</name>
      <address>
        <city>Des Moines</city>
        <state>Iowa</state>
        <zip>50266</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eye Associates of Northeast Louisiana</name>
      <address>
        <city>West Monroe</city>
        <state>Louisiana</state>
        <zip>71291</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cumberland Valley Retina Consultants</name>
      <address>
        <city>Hagerstown</city>
        <state>Maryland</state>
        <zip>21740</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mid Atlantic Retina Specialists</name>
      <address>
        <city>Hagerstown</city>
        <state>Maryland</state>
        <zip>21740</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sierra Eye Associates</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ophthalmic Consultants of Long Island</name>
      <address>
        <city>Oceanside</city>
        <state>New York</state>
        <zip>11572</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sterling Research</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Black Hills Regional Eye Institute</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Research Institute of Texas</name>
      <address>
        <city>Abilene</city>
        <state>Texas</state>
        <zip>79606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Retina Associates</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Research Center, PLLC</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Specialists</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Consultants of Houston</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77384</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Strategic Clinical Research Group LLC</name>
      <address>
        <city>Willow Park</city>
        <state>Texas</state>
        <zip>76087</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Piedmont Eye Center</name>
      <address>
        <city>Lynchburg</city>
        <state>Virginia</state>
        <zip>24502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Center NW PLLC</name>
      <address>
        <city>Silverdale</city>
        <state>Washington</state>
        <zip>98383</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>May 13, 2019</study_first_submitted>
  <study_first_submitted_qc>May 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 16, 2019</study_first_posted>
  <last_update_submitted>March 9, 2020</last_update_submitted>
  <last_update_submitted_qc>March 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Age-related macular degeneration</keyword>
  <keyword>Choroidal neovascularization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sunitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

